MetaCap

Arvinas Inc. (ARVN)

NASDAQ: ARVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.46-0.28 (-4.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ARVN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$423.03M
EPS (TTM)
-$0.08
52-week range
6.33 – 14.51
Day range
6.41 – 6.82
Volume / Avg
1.11M / 848.52K
Beta
—

52-week range

$6.33$14.51

ARVN stock today

Arvinas (ARVN) closed at $6.46 on Nov 20, down 4.15% (-$0.28), versus the S&P 500's 3.70% decline. Shares are 55.5% below their 52-week high of $14.51, set on Mar 10, 2026 and 2.1% above the 52-week low of $6.33, near the bottom of the past year's range. ARVN is down 45.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 43.9%.

Arvinas has posted a net loss over the last twelve months (EPS of -$0.08), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Arvinas

Company profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Randy Teel Ph.D.
Headquarters
New Haven, CT
Employees
246
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Arvinas generated $262.6 million in revenue, down 0.3% from fiscal 2024, its first annual decline since 2023. Arvinas reported a net loss of $80.8 million, compared with a loss of $198.9 million a year earlier. Operating margin was -45.1%.

Arvinas annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$262.60M$263.40M$78.50M$131.40M$53.60M
Growth-0.30%+235.54%-40.26%+145.15%+106.95%
Net income$-80.80M$-198.90M$-367.30M$-282.50M$-191.00M
EPS (diluted)$-1.14$-2.77$-6.62$-5.31$-3.82

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$14.00+116.72%

  • Strong buy 2
  • Buy 5
  • Hold 8
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.82 vs $-0.80
Surprise
-2.50%

ARVN news

All ARVN news

Arvinas peers

Health Care sector
ARVN peer companies
CompanyPrice% ChgMarket capCompare
PRTAProthena Corporation plc8.22-2.14%$422.10Mvs ARVN
CRMDCorMedix Inc.5.27+3.74%$419.16Mvs ARVN
OVIDOvid Therapeutics Inc.2.20-5.98%$415.21Mvs ARVN
EOLSEvolus Inc.6.52-6.86%$431.55Mvs ARVN
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs ARVN
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs ARVN
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs ARVN
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs ARVN

Indexes, lists and sector

Arvinas stock FAQ

What is Arvinas's stock price today?

ARVN last traded at $6.46 as of Nov 20, 4:00 PM EST, down 4.15% on the day. Prices are delayed at least 15 minutes.

Who is Arvinas's CEO?

Dr. Randy Teel Ph.D. is the chief executive officer of Arvinas Inc., which has about 246 employees.

What is the ARVN 52-week high?

The 52-week high for ARVN is $14.51 and the 52-week low is $6.33. The stock is currently 55.5% below its high.

Compare ARVN